London, UK 11/26/18; Chicago, IL 11/26/18—Life sciences firm LGC has acquired SeraCare Life Sciences from Linden Capital Partners for an undisclosed amount. SeraCare Life Sciences provides QC materials for infectious disease testing and NGS. Product lines include bulk plasma, panels for developing diagnostic assays and clinical controls for instrument calibration. “The team will be a natural fit and addition to our existing calibration verification business, providing an expanded portfolio of quality control solutions to customers,” stated Euan O’Sullivan, managing director, LGC’s Standards division. “This significant acquisition will also strengthen our presence in the fast growing molecular diagnostics and NGS reference materials market, complementing our genomics offering.” SeraCare, which has 170 employees, will continue to operate from its US facilities.

This purchase expands LGC Standards’ reference standards for a fast growing market, diversifying its life science offerings. Linden Capital acquired SeraCare in 2012 for $81 million, taking the company private (see IBO 5/31/12). PE Hub reports an approximately 4x return on the investment.